Dexcom Announces Dexcom Flex CGM for Type 2 Diabetes in Germany
DexCom, Inc. has announced the launch of Dexcom Flex, a new continuous glucose monitoring system tailored for adults with Type 2 diabetes who are not on intensive insulin therapy. This system aims to expand access to CGM technology for users on basal insulin, oral medications, or GLP-1 receptor agonists, and will soon be available in Germany.
SAN DIEGO & EDINBURGH, Scotland–(BUSINESS WIRE)–DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D